AGP Executive Report
Last update: 5 hours agoCancer Care Update: A Dana-Farber/Harvard-led ARACOG phase 2 analysis reports greater cognitive score decline with enzalutamide than darolutamide in prostate cancer, adding a new survivorship consideration for clinicians. Menopause & Sleep: Two studies spotlight women’s health—elinzanetant (NIRVANA) showed objective sleep improvements in postmenopausal vasomotor symptoms, and surgical menopause was linked to worse sexual and urinary symptoms than natural menopause. Nursing-Led Oncology Education: A nursing-centered briefing focuses on DLL3-directed therapies in small cell lung cancer, emphasizing toxicity monitoring and patient education. Narcolepsy Treatment Progress: Alkermes presented detailed positive Vibrance-2 phase 2 results for alixorexton in narcolepsy type 2, improving wakefulness and sleepiness. Public Health & Safety: Boston’s opioid overdose deaths fell to the lowest in a decade, with expanded naloxone access and training credited. Health Data Privacy: A report warns that the AI “gold rush” can put protected health information at risk, citing a major breach tied to an AI telehealth weight-loss provider. Massachusetts Community Health: The state’s beach water-quality dashboard is being updated hourly during beach season, with multiple sites listed as conditions change.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
